These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 761177)

  • 21. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
    Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
    Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
    Eagan RT; Carr DT; Frytak S; Rubin J; Lee RE
    Cancer Treat Rep; 1976 Jul; 60(7):949-51. PubMed ID: 64298
    [No Abstract]   [Full Text] [Related]  

  • 23. An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer.
    Rubin J; Decker DA; Ahmann DL; Eagan RT; Ingle JN; Hahn RG
    Oncology; 1980; 37(3):149-51. PubMed ID: 7360486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.
    Hansen MM; Bloomfield CD; Jørgensen J; Ersbøll J; Pedersen-Bjergaard J; Blom J; Nissen NI
    Cancer Treat Rep; 1980; 64(10-11):1135-7. PubMed ID: 7459900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of anaplastic carcinoma of the lung with VP 16-213].
    Sanz Ortíz J; Saiz García F
    Med Clin (Barc); 1982 Oct 16-31; 79(7):322-4. PubMed ID: 6294420
    [No Abstract]   [Full Text] [Related]  

  • 26. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside).
    Hansen M; Hirsch F; Dombernowsky P; Hansen HH
    Cancer; 1977 Aug; 40(2):633-7. PubMed ID: 196736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study.
    O'Bryan RM; Crowley JJ; Kim PN; Epstein RB; Neilan B; Coltman CA; Stuckey WJ; Pazdur R
    Cancer; 1990 Feb; 65(4):856-60. PubMed ID: 2153435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose etoposide (VP-16) in small-cell lung cancer.
    Greco FA; Johnson DH; Hande KR; Porter LL; Hainsworth JD; Wolff SN
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):42-4. PubMed ID: 2983434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VP-16-213 in the treatment of stage III and IV diffuse large cell lymphoma.
    Jacobs P; King HS; Dent DM; Hayes M
    Cancer; 1985 Sep; 56(5):1006-13. PubMed ID: 3893681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma.
    Newlands ES
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):37-41. PubMed ID: 2579442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of VP-16 in the treatment of small-cell lung cancer: studies of the West of Scotland Lung Cancer Group.
    Banham S; Dorward A; Hutcheon A; Ahmedzai S; Cunningham D; Burnett A; Soukop M; Lucie N; Kaye S
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):2-6. PubMed ID: 2983433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combination of etoposide with cisplatin or cyclophosphamide in the treatment of mouse Lewis lung carcinoma].
    Uchida T; Okamoto K; Nishikawa K; Takahashi K
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):75-9. PubMed ID: 3753643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer.
    Creagan ET; Eagan RT; Kvols LK
    Oncology; 1981; 38(5):260-1. PubMed ID: 7196561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B.
    Nissen NI; Pajak TF; Leone LA; Bloomfield CD; Kennedy BJ; Ellison RR; Silver RT; Weiss RB; Cuttner J; Falkson G; Kung F; Bergevin PR; Holland JF
    Cancer; 1980 Jan; 45(2):232-5. PubMed ID: 6985831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensive induction therapy for small cell carcinoma of the lung.
    Abeloff MD; Ettinger DS; Khouri NF; Lenhard RE
    Cancer Treat Rep; 1979 Apr; 63(4):519-24. PubMed ID: 221117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
    Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].
    Nakada H; Ogawa M; Ingaki J; Horikoshi N; Inoue K; Usui N; Adachi K; Tada A; Yamazaki H; Mukaiyama T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1644-8. PubMed ID: 6476837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
    Wolff SN; Fer MF; McKay CM; Hande KR; Hainsworth JD; Greco FA
    J Clin Oncol; 1983 Nov; 1(11):701-5. PubMed ID: 6366131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.